Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Transdermal buprenorphine controls central neuropathic pain.

Weiner M, Sarantopoulos C, Gordon E.

J Opioid Manag. 2012 Nov-Dec;8(6):414-5. doi: 10.5055/jom.2012.0141.

PMID:
23264319
2.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
3.

Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.

Canneti A, Luzi M, Di Marco P, Cannata F, Pasqualitto F, Spinoglio A, Reale C.

Minerva Anestesiol. 2013 Aug;79(8):871-83. Epub 2013 Apr 5.

PMID:
23558760
4.

Buprenorphine for neuropathic pain--targeting hyperalgesia.

Induru RR, Davis MP.

Am J Hosp Palliat Care. 2009 Dec-2010 Jan;26(6):470-3. doi: 10.1177/1049909109341868. Epub 2009 Aug 7.

PMID:
19666890
5.

Transdermal buprenorphine for central neuropathic pain: clinical reports.

Guetti C, Angeletti C, Marinangeli F, Ciccozzi A, Baldascino G, Paladini A, Varrassi G.

Pain Pract. 2011 Sep-Oct;11(5):446-52. doi: 10.1111/j.1533-2500.2010.00434.x. Epub 2010 Dec 29.

PMID:
21199314
7.

Buprenorphine--a review of its role in neuropathic pain.

Hans G.

J Opioid Manag. 2007 Jul-Aug;3(4):195-206. Review.

PMID:
17957979
8.

A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report.

Leppert W.

Am J Hosp Palliat Care. 2014 Feb;31(1):101-4. doi: 10.1177/1049909112472722. Epub 2013 Jan 23.

PMID:
23349342
9.

Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.

Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr.

Pain Physician. 2012 Jul;15(3 Suppl):ES59-66.

10.

Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.

Lundorff L, Sjøgren P, Hansen OB, Jonsson T, Nielsen PR, Christrup L.

J Opioid Manag. 2013 Jul-Aug;9(4):255-62. doi: 10.5055/jom.2013.0166.

PMID:
24353018
11.

Pediatric palliative care: use of opioids for the management of pain.

Zernikow B, Michel E, Craig F, Anderson BJ.

Paediatr Drugs. 2009;11(2):129-51. doi: 10.2165/00148581-200911020-00004. Review.

PMID:
19301934
12.
13.

[Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain].

Likar R, Griessinger N, Sadjak A, Sittl R.

Wien Med Wochenschr. 2003;153(13-14):317-22. German.

PMID:
12924108
14.

Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.

Davis MP.

J Support Oncol. 2012 Nov-Dec;10(6):209-19. doi: 10.1016/j.suponc.2012.05.002. Epub 2012 Jul 17. Review.

PMID:
22809652
16.

Transdermal buprenorphine.

Evans HC, Easthope SE.

Drugs. 2003;63(19):1999-2010; discussion 2011-2. Review.

PMID:
12962515
17.

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.

Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A.

Clin Ther. 2009 Oct;31(10):2134-8. doi: 10.1016/j.clinthera.2009.10.013.

PMID:
19922884
18.

Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies.

Likar R, Sittl R.

Anesth Analg. 2005 Mar;100(3):781-5, table of contents.

PMID:
15728068
19.

Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.

McCormick Z, Chu SK, Chang-Chien GC, Joseph P.

Pain Med. 2013 Aug;14(8):1187-91. doi: 10.1111/pme.12135. Epub 2013 May 3.

PMID:
23647815
20.

Supplemental Content

Support Center